While a gene dose effect of Tri12+ on MDM2 expression could influence maximal p53 levels via MDM2-mediated degradation of p53, a past study showed no difference in baseline MDM2 protein levels within Tri12+ and CLL without this aberration [120]. This evidence concerns the gene MDM2 and B-cell chronic lymphocytic leukemia.